公开(公告)号：US20190040141A1

公开(公告)日：2019-02-07

申请号：US15955304

申请日：2018-04-17

Applicant: Amgen Inc.

Inventor： Pedro J. BELTRAN ,  Frank J. CALZONE ,  Gregory FRIBERG ,  Christopher HAQQ ,  Anthony W. TOLCHER

IPC: C07K16/28

Abstract: The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.

公开(公告)号：US20200009204A1

公开(公告)日：2020-01-09

申请号：US16493376

申请日：2018-03-14

Applicant: AMGEN INC.

Inventor： Pedro J. BELTRAN ,  Courtney BEERS ,  Keegan COOKE

IPC: A61K35/763 ,  C07K16/28 ,  A61P35/00

Abstract: The present invention relates to the use of oncolytic viruses (e.g., talimogene laherparepvec), either alone or in combination with immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 compounds such an antibodies) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses, either alone or in combination with immune checkpoint inhibitors.